A Phase 1, Randomized, Double Blind, Placebo-Controlled, Single Ascending Dose Study in Healthy Participants Followed by a Phase 2a Open Label Study in Participants with PNH and Residual Anemia to Evaluate the Safety, Tolerability, PK and PD of ADX-038

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 19 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ADX 038
Indications Paroxysmal nocturnal haemoglobinuria
Focus Adverse reactions; First in man
Sponsors ADARx Pharmaceuticals

Most Recent Events

15 Nov 2024 Planned number of patients changed from 53 to 50, Phase has been changed to Phase 1/2 and sequential has been added to design terms.
15 Nov 2024 Planned End Date changed from 30 Jun 2025 to 30 Sep 2026.
15 Nov 2024 Planned primary completion date changed from 30 Nov 2024 to 30 Mar 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight